Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
HIV – Antiretroviral Therapy in Adults By Prof CN Menezes References: 1. WHO. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access. Progress report 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. Accessed August 2013. 2. UNAIDS World AIDS Day Report – Results. 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiolog y/2012/gr2012/JC2434_WorldAIDSday_results_en.pdf. Accessed August 2013. 3. Statistics South Africa. Mid year population estimates 2011. Available at: http://www.statssa.gov.za/Publications/P0302/P03022013.pdf. Accessed August 2013. 4. Fanales-Belasio E, et al. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita 2010; 46(1):5-14. 5. Southern African HIV Clinicians Society. Guidelines for Antiretroviral Therapy in Adults, September 2012. Available at: http://www.sahivsoc.org/upload/documents/Guidelines%20for%20antiretrovira l%20treatment%20therapy%20in%20adults,%20September%202012.pdf. Accessed August 2013. 6. National Department of Health. The South African Antiretroviral Treatment Guidelines 2013: Available at: http://www.sahivsoc.org/upload/documents/2013%20ART%20GuidelinesShort%20Combined%20FINAL%20draft%20guidelines%2014%20March%20 2013.pdf. Accessed August 2013. 7. Antiretroviral Treatment of Adult HIV Infection: 2012 recommendations of the International Antiviral Society – USA Panel. Available at: http://jama.jamanetwork.com/article.aspx?articleid=1221704. Accessed August 2013. 8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services (DHHS) 2013. Available at: http://www.guideline.gov/content.aspx?id=43783. Accessed August 2013. 9. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. June 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Accessed August 2013. 10. Williams I, et al. British HIV Association guidelines for the treatment of HIV-1positive adults with antiretroviral therapy 2012. HIV Med. 2012; 13: 1-6. 11. European AIDS Clinical Society Guidelines. 2012. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACSPdf/EacsGuidelines-v6.1-2edition.pdf . Accessed August 2013. 12. Cohen MS, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. 13. Schowalter L, Conradie F. Approaches to tenofovir and abacavir drug shortages in South Africa: a guide for clinicians. SAJHIVMED 2012; 13(2):567. 14. John MA, et al. Lamivudine-induced red cell aplasia. J Med Microbiol. 2008; 57(8):1032-5. 15. Falutz J. Therapy insight: shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab 2007; 3(9):651-61. 16. Kranick SM, Nath A. Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum (Minneap Minn). 2012; 18 (6 Infectious Disease):1319-37. 17. Jones M, Núñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis. 2012; 32(2):167-76. 18. Scherzer R, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012; 26(7):867-75. 19. Armstrong WS. The immune reconstitution inflammatory syndrome: a clinical update. Curr Infect Dis Rep. 2013; 15(1):39-45.